ONCOLOGY
also shape population-level cancer strategies, enabling risk prediction, earlier intervention, and continuous disease monitoring. At Source BioScience, we are aligning to this vision. By integrating our established cellular and digital pathology expertise with expanding clinical genomics and molecular diagnostics capabilities, we are building the infrastructure required for multi- modal, precision-led cancer diagnostics. Our goal is to create a connected diagnostic ecosystem, one that supports healthcare providers from early detection to treatment direction.
References 1 World Health Organization. Cancer.
(WHO, 2025)
www.who.int/health-topics/ cancer
Fully integrated laboratories will be key to sustaining diagnostic quality, accelerating turnaround times, and delivering the personalised insights for modern oncology.
By identifying molecular drivers and therapeutic vulnerabilities, such tools embody the evolution of oncology diagnostics from detection to direction.
Integration as the enabler Comprehensive assessment of tumour histopathology and genomic profile has become essential for precise therapeutic decision-making. Increasingly, pathologists and molecular scientists are working side by side, integrating tissue morphology with genomic and transcriptomic data to create a unified picture of each patient’s cancer. This growing connectivity is transforming laboratory medicine, turning the diagnostic process into an interconnected network that links screening, tissue analysis, molecular profiling, and clinical interpretation.
As oncology diagnostics become
more complex, integration between laboratory infrastructure, informatics systems, and clinical delivery is now critical. The acquisition of Cambridge Clinical Laboratories (CCL) by Source BioScience represents a significant step toward this unified model. By combining accredited clinical testing facilities with advanced molecular and genomic capabilities, Source BioScience is building a connected oncology diagnostic network under an overarching, quality-assured framework. This integration enables seamless progression from sample collection and processing through to molecular analysis and biomarker reporting. By aligning clinical genomics with established expertise in cellular and digital pathology, Source BioScience
is driving the adoption of multi-modal datasets into clinical practice. This holistic approach supports more comprehensive tumour profiling and strengthens the bridge between research innovation and real-world clinical decision-making. As cancer incidence rises and testing volumes increase, such integrated laboratory models will be key to sustaining diagnostic quality, accelerating turnaround times, and delivering the personalised insights that modern oncology demands.
The future
The next decade of oncology diagnostics will be defined by integration, automation, and personalisation. Advances in liquid biopsy, multi-omic profiling, and AI-assisted pathology are already expanding the reach and precision of modern cancer care. These technologies are making molecular insight more accessible, real-time, and actionable, guiding decisions from screening and early detection through to surveillance and relapse monitoring. Despite remarkable progress in many cancers, significant challenges remain. Survival rates for certain tumour types, such as pancreatic cancer, remain stubbornly low, largely due to late-stage diagnosis, with only around 10% of patients surviving beyond five years.7 However, innovation in this space is accelerating. Emerging biomarker assays, such as PancRISK (Procyon), are showing encouraging data for earlier, non-invasive detection.
Looking ahead, diagnostics will not only personalise treatment but will
WWW.PATHOLOGYINPRACTICE.COM DECEMBER 2025
2 Department of Health and Social Care. 10 Year Health Plan for England: fit for the future. (
Gov.uk, 2025)
https://www.gov.uk/ government/publications/10-year-health- plan-for-england-fit-for-the-future
3 Prostate Cancer Research. Socio-economic Impact of Prostate Cancer Screening. (PCR, 2024)
https://www.prostate-
cancer-research.org.uk/wp-content/ uploads/2024/11/PCR_Socioeconomic_ Impact_Prostate_Cancer_Screening_ Nov24-v1.0.pdf
4 Saemundsson A, Xu LD, Meisgen F, Cao R, Ahlgren G. Validation of the prognostic value of a three-gene signature and clinical parameters-based risk score in prostate cancer patients. Prostate. 2023;83(12):1133-1140. doi:10.1002/ pros.24530
5 Coleman R, Hall A, Albanell J, et al. Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial. Lancet Oncol. 2017;18(11):1543- 1552. doi:10.1016/S1470-2045(17)30603-4
6 Carapinha JL, Tercero JC, van den Berg R, et al. Economic impact of MAF testing for adjuvant bisphosphonate therapy in early breast cancer: a multi-regional budget impact analysis from a payer perspective. J Med Econ. 2025;28(1):1285-1297. doi:10.1080/13696998.2025.2543212
7 Farr KP, Moses D, Haghighi KS, Phillips PA, Hillenbrand CM, Chua BH. Imaging Modalities for Early Detection of Pancreatic Cancer: Current State and Future Research Opportunities. Cancers (Basel). 2022;14(10):2539. doi:10.3390/ cancers14102539
Source BioScience 0115 973 9012
enquiries@sourcebioscience.com
www.sourcebioscience.com
29
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
